Business
Crinetics to Highlight Broad Pipeline at ENDO 2023
Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for Entrepreneurship SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics
About this update from Crinetics Pharmaceuticals, Inc.
[{"type":"text","content":"Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for Entrepreneurship\nSAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the Endocrine Society’s annual meeting, which is being held June 15-18, 2023 in Chicago, Illinois. Two presentations will provide additional clinical evidence and patient-reported data for paltusotine, an experimental, once-daily, oral, small molecule somatostatin receptor type 2 (SST2) agonist in Phase 3 clinical development for the treatment of acromegaly. An upcoming oral presentation will review previously reported two-year data from the company’s ACROBAT Advance open-label extension study of paltusotine in acromegaly. The presentation will be delivered by Monica R. Gadelha, M.D., Ph.D., professor of endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro and a principal investigator in the Phase 2 ACROBAT program. In addition to the maintenance of IGF-1 levels in Advance study participants, Dr. Gahelha will present an analysis of symptom control and other patient-reported outcomes as assessed using the Acromegaly Symptom Diary. In addition, Crinetics will highlight the results of in vivo studies from preclinical programs developing: (1) a parathyroid hormone receptor type 1 (PTH1R) antagonist for the treatment of primary hyperparathyroidism; and (2) a thyroid-stimulating hormone receptor (TSHR) antagonist for the treatment of Graves’ disease, an autoimmune disorder that can cause hyperthyroidism and the associated thyroid eye disease (orbitopathy). Additional details on the presentations are shown below: Title:Oral, Once-Daily, Paltusotine (Non-Peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy in Patients with Acromegaly is Associated with Long-Term Biochemical and Symptom Control and is Preferred Over Injectable Somatostatin-Receptor LigandsDate/Time:June 15th from 10:00 AM - 11:30 AM CTLocation:Oral Session OR01 - Neuroendocrinology: Molecular and Physiological Aspects Title:Discovery and Characterization of Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonists for the Treatment of Graves’ DiseaseDate/Time:June 16th from 12:00pm - 1:00pm CTLocation:Poster FRI-546 ...